Who is sponsoring NCT05513131?

NCT05513131 is sponsored by The First Affiliated Hospital with Nanjing Medical University.

What drugs are being tested in NCT05513131?

Interventions in NCT05513131: Venetoclax；Azacitidine；Homoharringtonine.

What condition does NCT05513131 study?

NCT05513131 studies Secondary Acute Myeloid Leukemia.

Is NCT05513131 still recruiting?

NCT05513131 is currently status unknown. Last updated 24 August 2022.

Last reviewed 2022-08-24 · How we verify

NCT05513131

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Study Protocol of Venetoclax Combined With Azacitidine and Harringtonine in the Treatment of sAML

Status unknown Phase 2 Last updated 24 August 2022

What this trial tests

Phase 2 trial testing Venetoclax；Azacitidine；Homoharringtonine in Secondary Acute Myeloid Leukemia in 30 participants. Status unknown.

Timeline

30 September 2021

Primary endpoint
30 September 2023

30 September 2025

Quick facts

Lead sponsor	The First Affiliated Hospital with Nanjing Medical University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	30 September 2021
Primary completion	30 September 2023
Estimated completion	30 September 2025
Sites	1 location across China

Drugs / interventions tested

Venetoclax；Azacitidine；Homoharringtonine — full drug profile →

Conditions studied

Secondary Acute Myeloid Leukemia — all drugs for Secondary Acute Myeloid Leukemia →

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Who can join

Adults 18 to 80, any sex, with Secondary Acute Myeloid Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This research is being done to assess the therapeutic efficacy and safety of a promising regimen (Venetoclax combined with Azacitidine and Harringtonine) in patients with secondary AML This study involves the following: Venetoclax combined with Azacitidine and Harringtonine

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

How I treat secondary acute myeloid leukemia.
Green SD, Wang ES. · · 2025 · cited 8× · PMID 39356870 · DOI 10.1182/blood.2024024011

Verify or expand the search:

Other recruiting trials for Secondary Acute Myeloid Leukemia

Currently open trials in the same condition.

NCT06928662 — Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant · Phase 1, PHASE2 · recruiting
NCT05672147 — CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia · Phase 1 · recruiting
NCT05807932 — Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogen · Phase 1, PHASE2 · recruiting
NCT05139004 — 90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of H · Phase 1 · active not recruiting
NCT05584761 — Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML · Phase 1, PHASE2 · recruiting

Other The First Affiliated Hospital with Nanjing Medical University trials

Trials by the same sponsor.

NCT07377981 — An Exploratory Study of the Efficacy and Safety of Esketamine and Dexmedetomidine in Non-Intubated ICU Patients With Hyp · Phase 4 · not yet recruiting
NCT07523789 — Comparison of Chemotherapy and Immunotherapy in Neoadjuvant Therapy for TNBC · not yet recruiting
NCT07464756 — SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer · Phase 2 · not yet recruiting
NCT07482826 — Full-Endoscopic Decompression vs. Endoscopic Lumbar Fusion for Middle-Aged and Older Adults With Spinal Stenosis · NA · not yet recruiting
NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05513131 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital with Nanjing Medical University
Last refreshed: 24 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05513131.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing